The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1532605
This article is part of the Research Topic Community Series in Implications of Immune Landscape in Tumor Microenvironment: Volume II View all articles
Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer
Provisionally accepted- 1 Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
- 2 Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong Region, China
In the realm of oncology, the tumor microenvironment (TME)comprising extracellular matrix components, immune cells, fibroblasts, and endothelial cellsplays a pivotal role in tumorigenesis, progression, and response to therapeutic interventions. Initially, the TME exhibits tumor-suppressive properties that can inhibit malignant transformation. However, as the tumor progresses, various factors induce immune tolerance, resulting in TME behaving in a state that promotes tumor growth and metastasis in later stages. This state of immunosuppression is crucial as it enables TME to change from a role of killing tumor cells to a role of promoting tumor progression. Gastric cancer is a common malignant tumor of the gastrointestinal tract with an alarmingly high mortality rate. While chemotherapy has historically been the cornerstone of treatment, its efficacy in prolonging survival remains limited. The emergence of immunotherapy has opened new therapeutic pathways, yet the challenge of immune tolerance driven by the gastric cancer microenvironment complicates these efforts. This review aims to elucidate the intricate role of the TME in mediating immune tolerance in gastric cancer and to spotlight innovative strategies and clinical trials designed to enhance the efficacy of immunotherapeutic approaches. By providing a comprehensive theoretical framework, this review seeks to advance the understanding and application of immunotherapy in the treatment of gastric cancer, 3 ultimately contributing to improved patient outcomes.
Keywords: gastric cancer, Immunosuppression, Tumor Microenvironment, Immunotherapy, Metabolize
Received: 22 Nov 2024; Accepted: 30 Jan 2025.
Copyright: © 2025 He, Guan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yan Li, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.